Trial Profile
A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in HIV-uninfected Adults at Low Risk of HIV Infection
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs ALVAC HIV vCP2438 (Primary) ; MF 59
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 18 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results assessing effects of the 12-month booster on peak post-boost and memory vaccine-induced immune responses, presented at the 9th International AIDS Society Conference on HIV Science.
- 16 Dec 2015 New trial record